ticlopidine has been researched along with Necrosis in 22 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Necrosis: The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We compared the effects of a 600- versus a 300-mg LD of clopidogrel on inhibition of platelet aggregation, myonecrosis, and clinical outcomes in patients with NSTEACS undergoing an early invasive management strategy." | 9.14 | Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin ( Brieger, D; Chew, DP; Dick, R; Eccleston, D; Eikelboom, JW; Ferguson, L; French, J; Hockings, B; Rankin, J; Thom, J; Walters, D; Whelan, A; Yong, G, 2009) |
| "The purpose of this study was to evaluate the effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention (PCI) with glycoprotein (GP) IIb/IIIa blockade." | 9.13 | The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy. ( Buller, C; Densem, C; Fox, R; Fung, A; Jokhi, P; Mancini, GB; Ricci, D; Saw, J; Starovoytov, A; Walsh, S; Wong, G, 2008) |
| "A strategy of clopidogrel with GP IIb/IIIa blockade resulted in superior inhibition of inflammation and cardiac marker release, which was accompanied by superior platelet inhibition immediately after percutaneous coronary intervention compared with a strategy of clopidogrel alone." | 9.12 | Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. ( Bliden, KP; Gurbel, PA; Tantry, US, 2006) |
| "In patients with NSTE-ACS undergoing early invasive strategy, the adjunctive administration of upstream tirofiban did not reduce the peak values and the cumulative release of myocardial necrosis markers, compared with aspirin, heparin, and clopidogrel given on admission and associated with selective use of abciximab just before PCI." | 9.11 | Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstrea ( Badia, T; Bellandi, F; Dabizzi, RP; De Servi, S; Leoncini, M; Maioli, M; Politi, A; Toso, A, 2005) |
| "We sought to evaluate the influence of platelet reactivity after clopidogrel, as assessed by the VerifyNow point-of-care assay (Accumetrics, San Diego, California), on myonecrosis in low-to-intermediate risk patients undergoing percutaneous coronary intervention (PCI)." | 7.76 | Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. ( Barbato, E; D'Ambrosio, A; Di Sciascio, G; Gatto, L; Mangiacapra, F; Patti, G; Ricottini, E; Vizzi, V; Wijns, W, 2010) |
| " A significant dose-response was also observed for the vasodilator-stimulated phosphoprotein index, a measure of P2Y(12) receptor inhibition." | 6.72 | A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t ( Bal-dit-Sollier, C; Beygui, F; Collet, JP; Drouet, L; Henry, P; Lellouche, N; Meuleman, C; Milleron, O; Montalescot, G; Sideris, G; Slama, M; Steg, PG, 2006) |
| "Aspirin response was assessed by measuring the residual ability of platelets to generate thromboxane, calculated as the difference between thromboxane B2 levels in serum and plasma, [TxB2]S-P." | 5.42 | Dual antiplatelet response during PCI: VerifyNow P2Y12 predicts myocardial necrosis and thromboxane B2 generation confirms wide variation in aspirin response. ( Good, RI; Goodall, AH; James, TE; McConnachie, A; McGarrity, A; Miller, H; Oldroyd, KG, 2015) |
| "In the PRATO-ACS trial, 504 consecutive statin-naïve non-ST-elevation acute coronary syndrome patients scheduled for early invasive strategy and pretreated with high-dose clopidogrel were randomly assigned to rosuvastatin (40 mg on admission followed by 20 mg/d; statin group, n = 252) or no statin treatment (control group, n = 252)." | 5.19 | Early high-dose rosuvastatin and cardioprotection in the protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome (PRATO-ACS) study. ( Badia, T; Bellandi, F; Leoncini, M; Maioli, M; Toso, A; Tropeano, F; Villani, S, 2014) |
| "We compared the effects of a 600- versus a 300-mg LD of clopidogrel on inhibition of platelet aggregation, myonecrosis, and clinical outcomes in patients with NSTEACS undergoing an early invasive management strategy." | 5.14 | Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin ( Brieger, D; Chew, DP; Dick, R; Eccleston, D; Eikelboom, JW; Ferguson, L; French, J; Hockings, B; Rankin, J; Thom, J; Walters, D; Whelan, A; Yong, G, 2009) |
| "The purpose of this study was to evaluate the effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention (PCI) with glycoprotein (GP) IIb/IIIa blockade." | 5.13 | The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy. ( Buller, C; Densem, C; Fox, R; Fung, A; Jokhi, P; Mancini, GB; Ricci, D; Saw, J; Starovoytov, A; Walsh, S; Wong, G, 2008) |
| "1% male) patients receiving 300 mg daily enteric coated aspirin for at least 7 days with documented coronary artery disease were included in the study." | 5.13 | Effects of persistent platelet reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions. ( Aydinalp, A; Ertan, C; Gulmez, O; Kaynar, G; Konas, D; Muderrisoglu, H; Ozin, B; Yildirir, A, 2008) |
| "A strategy of clopidogrel with GP IIb/IIIa blockade resulted in superior inhibition of inflammation and cardiac marker release, which was accompanied by superior platelet inhibition immediately after percutaneous coronary intervention compared with a strategy of clopidogrel alone." | 5.12 | Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. ( Bliden, KP; Gurbel, PA; Tantry, US, 2006) |
| "In elective stenting without clopidogrel pretreatment, use of a GPIIb/IIIa inhibitor produces superior platelet inhibition and lower myocardial necrosis compared with high-dose (600 mg) or standard-dose (300 mg) clopidogrel loading alone." | 5.11 | Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. ( Bliden, KP; Gurbel, PA; Hayes, KM; Tantry, US; Yoho, JA; Zaman, KA, 2005) |
| "In patients with NSTE-ACS undergoing early invasive strategy, the adjunctive administration of upstream tirofiban did not reduce the peak values and the cumulative release of myocardial necrosis markers, compared with aspirin, heparin, and clopidogrel given on admission and associated with selective use of abciximab just before PCI." | 5.11 | Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstrea ( Badia, T; Bellandi, F; Dabizzi, RP; De Servi, S; Leoncini, M; Maioli, M; Politi, A; Toso, A, 2005) |
| " This review examines the role of clopidogrel in decreasing periprocedural myonecrosis following percutaneous coronary intervention (PCI)." | 4.85 | Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention. ( Dasgupta, A; Mukherjee, D, 2009) |
| "We sought to evaluate the influence of platelet reactivity after clopidogrel, as assessed by the VerifyNow point-of-care assay (Accumetrics, San Diego, California), on myonecrosis in low-to-intermediate risk patients undergoing percutaneous coronary intervention (PCI)." | 3.76 | Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. ( Barbato, E; D'Ambrosio, A; Di Sciascio, G; Gatto, L; Mangiacapra, F; Patti, G; Ricottini, E; Vizzi, V; Wijns, W, 2010) |
| " Thus, we assessed whether platelet function under high shear rates (collagen adenosine diphosphate closure times [CADP-CTs]) measured with the platelet function analyzer (PFA-100) may be enhanced in patients with myocardial infarction (MI) and whether it may predict the extent of myocardial damage as measured by creatine kinase (CK-MB) or troponin T (TnT) levels." | 3.72 | Platelet function predicts myocardial damage in patients with acute myocardial infarction. ( Domanovits, H; Frossard, M; Fuchs, I; Hsieh, K; Jilma, B; Laggner, AN; Leitner, JM; Losert, H; Schreiber, W; Vlcek, M, 2004) |
| " A significant dose-response was also observed for the vasodilator-stimulated phosphoprotein index, a measure of P2Y(12) receptor inhibition." | 2.72 | A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t ( Bal-dit-Sollier, C; Beygui, F; Collet, JP; Drouet, L; Henry, P; Lellouche, N; Meuleman, C; Milleron, O; Montalescot, G; Sideris, G; Slama, M; Steg, PG, 2006) |
| "Aspirin response was assessed by measuring the residual ability of platelets to generate thromboxane, calculated as the difference between thromboxane B2 levels in serum and plasma, [TxB2]S-P." | 1.42 | Dual antiplatelet response during PCI: VerifyNow P2Y12 predicts myocardial necrosis and thromboxane B2 generation confirms wide variation in aspirin response. ( Good, RI; Goodall, AH; James, TE; McConnachie, A; McGarrity, A; Miller, H; Oldroyd, KG, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (72.73) | 29.6817 |
| 2010's | 6 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Leoncini, M | 2 |
| Toso, A | 2 |
| Maioli, M | 2 |
| Tropeano, F | 1 |
| Badia, T | 2 |
| Villani, S | 1 |
| Bellandi, F | 2 |
| Good, RI | 1 |
| McGarrity, A | 1 |
| James, TE | 1 |
| Miller, H | 1 |
| McConnachie, A | 1 |
| Goodall, AH | 1 |
| Oldroyd, KG | 1 |
| Ivandic, BT | 1 |
| Kurz, K | 1 |
| Keck, F | 1 |
| Staritz, P | 1 |
| Lehrke, S | 1 |
| Katus, HA | 1 |
| Giannitsis, E | 1 |
| Yong, G | 1 |
| Rankin, J | 1 |
| Ferguson, L | 1 |
| Thom, J | 1 |
| French, J | 1 |
| Brieger, D | 1 |
| Chew, DP | 1 |
| Dick, R | 1 |
| Eccleston, D | 1 |
| Hockings, B | 1 |
| Walters, D | 1 |
| Whelan, A | 1 |
| Eikelboom, JW | 1 |
| Dasgupta, A | 1 |
| Mukherjee, D | 1 |
| Saw, J | 1 |
| Densem, C | 1 |
| Walsh, S | 1 |
| Jokhi, P | 1 |
| Starovoytov, A | 1 |
| Fox, R | 1 |
| Wong, G | 1 |
| Buller, C | 1 |
| Ricci, D | 1 |
| Mancini, GB | 1 |
| Fung, A | 1 |
| Stellos, K | 1 |
| Bigalke, B | 1 |
| Stakos, D | 1 |
| Henkelmann, N | 1 |
| Gawaz, M | 1 |
| Sullivan, BP | 1 |
| Wang, R | 1 |
| Tawfik, O | 1 |
| Luyendyk, JP | 1 |
| Mangiacapra, F | 1 |
| Barbato, E | 1 |
| Patti, G | 2 |
| Gatto, L | 1 |
| Vizzi, V | 1 |
| Ricottini, E | 1 |
| D'Ambrosio, A | 1 |
| Wijns, W | 1 |
| Di Sciascio, G | 2 |
| Bordeaux, JS | 1 |
| Martires, KJ | 1 |
| Goldberg, D | 1 |
| Pattee, SF | 1 |
| Fu, P | 1 |
| Maloney, ME | 1 |
| Frossard, M | 1 |
| Fuchs, I | 1 |
| Leitner, JM | 1 |
| Hsieh, K | 1 |
| Vlcek, M | 1 |
| Losert, H | 1 |
| Domanovits, H | 1 |
| Schreiber, W | 1 |
| Laggner, AN | 1 |
| Jilma, B | 1 |
| Gurbel, PA | 2 |
| Bliden, KP | 2 |
| Zaman, KA | 1 |
| Yoho, JA | 1 |
| Hayes, KM | 1 |
| Tantry, US | 2 |
| Politi, A | 1 |
| De Servi, S | 1 |
| Dabizzi, RP | 1 |
| Gulec, S | 1 |
| Ozdol, C | 1 |
| Rahimov, U | 1 |
| Atmaca, Y | 1 |
| Kumbasar, D | 1 |
| Erol, C | 1 |
| Pasceri, V | 1 |
| Nusca, A | 1 |
| Defuentes, G | 1 |
| Lecoules, S | 1 |
| Vedrine, L | 1 |
| Coutant, G | 1 |
| Baranger, B | 1 |
| Algayres, JP | 1 |
| Moore, RK | 1 |
| Lowe, R | 1 |
| Grayson, AD | 1 |
| Morris, JL | 1 |
| Perry, RA | 1 |
| Stables, RH | 1 |
| Montalescot, G | 1 |
| Sideris, G | 1 |
| Meuleman, C | 1 |
| Bal-dit-Sollier, C | 1 |
| Lellouche, N | 1 |
| Steg, PG | 1 |
| Slama, M | 1 |
| Milleron, O | 1 |
| Collet, JP | 1 |
| Henry, P | 1 |
| Beygui, F | 1 |
| Drouet, L | 1 |
| Ersoy, A | 1 |
| Sevin, K | 1 |
| Sevin, A | 1 |
| Serel, S | 1 |
| Buch, AN | 1 |
| Singh, S | 1 |
| Roy, P | 1 |
| Javaid, A | 1 |
| Smith, KA | 1 |
| George, CE | 1 |
| Pichard, AD | 1 |
| Satler, LF | 1 |
| Kent, KM | 1 |
| Suddath, WO | 1 |
| Waksman, R | 1 |
| Gulmez, O | 1 |
| Yildirir, A | 1 |
| Kaynar, G | 1 |
| Konas, D | 1 |
| Aydinalp, A | 1 |
| Ertan, C | 1 |
| Ozin, B | 1 |
| Muderrisoglu, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Protective Effect of Rosuvastatin and Antiplatelet Therapy On Contrast-induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention; PRATO-ACS Trial[NCT01185938] | Phase 4 | 500 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention[NCT00111566] | Phase 4 | 624 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Effects of Ticagrelor Versus Prasugrel on Coronary Microcirculation in Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the PROtecting MICROcirculation During Coronary Angioplasty (PROMICRO)-3 Randomised Study[NCT05643586] | Phase 4 | 50 participants (Actual) | Interventional | 2017-12-01 | Completed | ||
| The Effect of Ticagrelor on Acute Coronary Syndrome Patients With Clopidogrel Resistance Undergoing Percutaneous Coronary Intervention[NCT01812330] | Phase 3 | 180 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| A Pilot Study of The Effects of a Single High Dose Bolus Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention[NCT00407771] | Phase 4 | 44 participants (Anticipated) | Interventional | 2007-11-30 | Not yet recruiting | ||
| "Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing One-stop Hybrid Coronary Revascularization"[NCT02513004] | Phase 4 | 60 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| Non-randomized, Open-label, Historical Control, Single Group Assignment Trial of a Reduced Dose of Unfractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions[NCT00735280] | Phase 4 | 2,505 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis.[NCT00360386] | Phase 2 | 110 participants | Interventional | 2004-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for ticlopidine and Necrosis
| Article | Year |
|---|---|
Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Creatine Kinase, MB Form; Drug Administrati | 2009 |
[Prevention of periprocedural myocardial damage in patients undergoing percutaneous coronary intervention].
Topics: Actuarial Analysis; Adenosine; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholestere | 2005 |
9 trials available for ticlopidine and Necrosis
11 other studies available for ticlopidine and Necrosis
| Article | Year |
|---|---|
Dual antiplatelet response during PCI: VerifyNow P2Y12 predicts myocardial necrosis and thromboxane B2 generation confirms wide variation in aspirin response.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies | 2015 |
Platelet-bound P-selectin expression in patients with coronary artery disease: impact on clinical presentation and myocardial necrosis, and effect of diabetes mellitus and anti-platelet medication.
Topics: Acute Coronary Syndrome; Angina Pectoris; Aspirin; Biomarkers; Blood Platelets; Clopidogrel; Coronar | 2010 |
Protective and damaging effects of platelets in acute cholestatic liver injury revealed by depletion and inhibition strategies.
Topics: 1-Naphthylisothiocyanate; Animals; Antibodies, Monoclonal; Biomarkers; Blood Coagulation; Blood Plat | 2010 |
Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Blood Platelets; Clopidogrel; Coronary Artery Dise | 2010 |
Prospective evaluation of dermatologic surgery complications including patients on multiple antiplatelet and anticoagulant medications.
Topics: Aged; Ambulatory Surgical Procedures; Antibiotic Prophylaxis; Anticoagulants; Clopidogrel; Dermatolo | 2011 |
Platelet function predicts myocardial damage in patients with acute myocardial infarction.
Topics: Abciximab; Adenosine Diphosphate; Aged; Antibodies, Monoclonal; Anticoagulants; Aspirin; Cardiovascu | 2004 |
Myonecrosis after elective percutaneous coronary intervention: effect of clopidogrel-statin interaction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Creatine Kinase, MB Form; Cytochrome P-450 CYP3A; | 2005 |
[Accelerated atheroma with prednisone and clopidogrel].
Topics: Aged; Atherosclerosis; Carotid Stenosis; Clopidogrel; Endarterectomy; Giant Cell Arteritis; Glucocor | 2006 |
A study comparing the incidence and predictors of creatine kinase MB and troponin T release after coronary angioplasty. Does Clopidogrel preloading reduce myocardial necrosis following elective percutaneous coronary intervention?
Topics: Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Cohort Studies; Coronary Disease; Creatine | 2007 |
Effects of clopidogrel on survival of rat skin flaps.
Topics: Animals; Clopidogrel; Graft Survival; Male; Necrosis; Platelet Aggregation Inhibitors; Random Alloca | 2007 |
Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; | 2007 |